| Literature DB >> 33773549 |
Tahir Maqbool1, Faheem Hadi1, Sehrish Razzaq1, Sadia Naz1, Saira Aftab1, Sameera Khurshid1, Sana Javaid Awan1, Aisha Nawaz1, Farah Abid1, Arif Malik1.
Abstract
BACKGROUND: Drug synergy is the combine effect of drug efficacy. Synergistic combinations of active ingredients have proven to be highly effective and more useful in therapeutics. In contrast, the individual effect of drug is usually undesirable and mostly used for selecting drug-resistant mutations. Purpose of this study was to check synergistic effects of both plants (Barbadensis miller and Marsdenia condurango) against liver and cervical cancer.Entities:
Keywords: Cytotoxicity; Gene expression; Protein expression; Synergistic effect
Year: 2021 PMID: 33773549 PMCID: PMC8286677 DOI: 10.31557/APJCP.2021.22.3.843
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Figure 1Figure Shows the IC50 of Barbadenesis miller (BE) and Marsdenia cundurango (CE).
IC50 of BE Extract and CE and Combined BE+CE (Synergistic Effects) Extracts
| Cell Line | Absorbance at 570nm for different samples | |||||||
|---|---|---|---|---|---|---|---|---|
| UT | 10µg/mL | 25µg/mL | 50µg/mL | 100µg/mL | 500 µg/mL | 1000 µg/mL | ||
| HeLa | BE | 0.907±0.0115 | 0.897±0.0153 | 0.840±0.0173 | 0.753±0.0153 | 0.620±0.0265 | 0.417±0.0289 | 0.317±0.0153 |
| CE | 0.907±0.0115 | 0.933±0.0208 | 0.823±0.0252 | 0.717±0.0473 | 0.550±0.0500 | 0.350±0.030 | 0.317±0.0153 | |
| BE+CE (1:1) | 0.907±0.0115 | 0.753±0.0451 | 0.453±0.0757 | 0.303±0.0057 | 0.267±0.0115 | -- | -- | |
| Hep G2 | BE | 1.00±0.0500 | 0.957± 0.0404 | 0.890±0.0361 | 0.790±0.0361 | 0.720±0.0265 | 0.477±0.0252 | 0.390±0.0361 |
| CE | 1.00±0.0500 | 1.16±0.0404 | 0.990±0.0361 | 0.803±0.0351 | 0.650±0.0500 | 0.403±0.00577 | 0.271±0.0258 | |
| BE+CE combined (1:1) | 1.000±0.0500 | 0.740±0.0529 | 0.530±0.0265 | 0.343±0.0153 | 0.283±0.0289 | -- | -- | |
Figure 2Figure Shows the IC50 of Combined/Synergistic BE+CE Extracts
IC50 of Combined BE+CE extracts for Trypan Blue, Crystal Violet and ELISA p53
| Mode of measurement | HeLa | HepG2 | ||
|---|---|---|---|---|
| TB | Relative percentage of live cells | Un treated | 100±0.000 | 100±0.000 |
| Treated with IC50 | 187±11.5 | 207±7.77 | ||
| CV | Absorbance taken at 570 nm | Un treated | 0.517±0.0207 | 0.4673±0.02022 |
| Treated with IC50 | 0.228±0.014 | 0.2633±0.2893 | ||
| ELISA p53 | Absorbance taken at 450 nm | Un treated | 0.540±0.0482 | 0.233±0.0257 |
| Treated with IC50 | 0.493±0.00781 | 0.268±0.0294 |
Figure 3Figure Shows the Combined/Synergistic Effects of Ethanolic Extract of Barbadensis miller (BE) and Marsdenia Cundurango (CE) in Trypan Blue Assay, Crystal Violet against HeLa and HepG2 Cells
Figure 4Muse Analysis of HeLa and HepG2 Cells
Figure 5Characterization of p53 Level in Untreated and plants extracts treated HeLa and HepG2 Cells in Synergism via ELISA
Figure 6Expression of p53 in Untreated and plants extracts treated HeLa and HepG2 Cells in Synergism via Immunocytochemistry
IC50 of Combined BE+CE Extracts GSH, SOD, CAT and LDH
| Assay | Mean + SD values | HeLa | HepG2 |
|---|---|---|---|
| GSH | Untreated | 0.517±0.0351 | 0.5039±0.03988 |
| BE+CE | 0.298±0.0107 | 0.3281±0.01893 | |
| SOD | Untreated | 0.561±0.0321 | 0.5613±0.05552 |
| BE+CE | 0.336±0.0222 | 0.3682±0.01900 | |
| CAT | Untreated | 0.517±0.0207 | 0.6068±0.02305 |
| BE+CE | 0.302±0.00650 | 0.3412±0.01000 |
Figure 8Figure Shows the Relative Gene Expression